Piscataway, NJ, March 1, 2023– Camber Pharmaceuticals is pleased to announce the addition of Valganciclovir for Oral Solution to its current portfolio.
Valganciclovir for Oral Solution is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for:
Adult Patients:
- Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
- Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.
Pediatric Patients:
- Prevention of CMV disease in kidney and heart transplant patients at high risk.
Valganciclovir for Oral Solution 50 mg/mL is available in 100mL bottles.
To find out more about Valganciclovir for Oral Solution please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]
